OCTS USA 2021 | Kisaco Research

OCTS USA 2021

Revolutionizing patient outcomes in cancer therapies

Download 2020 agenda

OCTS USA 2021

Boston, USA
29-30 June, 2021

“OCTS is a premier conference in the cell and gene therapy calendar, highly worthwhile”

Astellas

Why Attend

The Onco Cell Therapy Summit (OCTS), is an event that brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.

OCTS brings together the key decision-makers for T cell-based therapies as well those interest in harnessing alternative cell therapies in cancer treatments including macrophages and NK.

As well as increasing the efficacy of cell therapies, the other pillar of research is into driving a more affordable therapy. The other tracks will delve into best practices in the logistics and manufacturing of immuno-oncological cell therapies.

Each day of the summit will break down the key challenges in major topics within R&D and the Vein to Vein process.

Our 2020 Speakers

 

Carl June

Professor of Immunotherapy
University of Pennsyvania

Carl June

Professor of Immunotherapy
University of Pennsyvania

Carl June

Professor of Immunotherapy
University of Pennsyvania
 

Adlai Goldberg

Digital, Social and Commercial Innovation Life Sciences Leader
EY Global

Keenly focused on capturing opportunities and managing impacts created by the digital megatrend for the life sciences clients.

As EY Global Life Sciences Digital, Social and Commercial Innovation Leader, Adlai is focused on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases.

Adlai Goldberg

Digital, Social and Commercial Innovation Life Sciences Leader
EY Global

Adlai Goldberg

Digital, Social and Commercial Innovation Life Sciences Leader
EY Global

Keenly focused on capturing opportunities and managing impacts created by the digital megatrend for the life sciences clients.

As EY Global Life Sciences Digital, Social and Commercial Innovation Leader, Adlai is focused on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases.

Having a keen interest in different cultures, he has chosen to spend his career living and working around the world in many markets including Japan, Thailand, Hong Kong, Indonesia, Ukraine, Russia and Switzerland.

With more than 28 years of professional experience in media, communications and consulting to his credit, Adlai helped establish EY global social media services and analytics hub. Additionally, he has also helped launch the world’s first interactive television platform in Hong Kong.

Adlai earned an MBA in Marketing and Real Estate from Southern Methodist University and a BS in Accounting from Metropolitan State College. How Adlai is building a better working world “I have been blessed with two opportunities to make important contributions to this world. First, I helped directly support the reconstruction and rehabilitation of communities affected by the tsunami in 2004 that hit Indonesia, Sri Lanka and Thailand.

For three years, I worked with donors and helped nongovernmental organizations manage their financial resources in order to provide the greatest support possible. I also design and help manage a tsunami commemoration program on behalf of the Republic of Indonesia.

Second, I helped design the necessary digital infrastructure needed to support emerging individualized therapies that may, one day, help cure cancer and rare diseases.”

 

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr.

Knut Niss

Chief Technology Officer
Mustang Bio

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

 

 

Peter Emtage

SVP of Cell Therapy Research
Kite Pharma

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S.

Peter Emtage

SVP of Cell Therapy Research
Kite Pharma

Peter Emtage

SVP of Cell Therapy Research
Kite Pharma

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, he also was a post-doctoral fellow at the National Institutes of Health and held roles at Aventis Pasteur and Harvard Medical School.

 

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity
 

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute
 

Orlando Serani

Program Architecht CAR-T Advanced Cell Therapies Supply Chain
Jansen Pharmaceutical Companies of Johnson & Johnson

As of May 2018, Orlando leads the program strategy for the recently announced Chimeric Antigen Receptor T-Cells therapeutic area. This includes digital strategies, supply chain network design, and supply chain capability development for this therapy platform, currently targeted as a last line of defense for multiple myeloma.

Orlando Serani

Program Architecht CAR-T Advanced Cell Therapies Supply Chain
Jansen Pharmaceutical Companies of Johnson & Johnson

Orlando Serani

Program Architecht CAR-T Advanced Cell Therapies Supply Chain
Jansen Pharmaceutical Companies of Johnson & Johnson

As of May 2018, Orlando leads the program strategy for the recently announced Chimeric Antigen Receptor T-Cells therapeutic area. This includes digital strategies, supply chain network design, and supply chain capability development for this therapy platform, currently targeted as a last line of defense for multiple myeloma.

Previously, Orlando was Vice President, Information Technology, Customer and Logistics Services: the logistics and customer services organization which serves all Johnson & Johnson businesses globally. Additionally, he also led the technology organization of the Consumer Medical Devices supply chain, including diabetes, contact lenses, and vision surgery products and services.
Orlando began his career with the Johnson & Johnson Consumer business in Italy in 1988. After a Foreign Service National assignment with the United States Information Agency in Rome, Italy from 1990 until 1992, he rejoined Johnson & Johnson’s Ortho-Clinical Diagnostics, where he held diverse positions in R&D, Sales and Marketing, and IT. In 2010, as part of the announcement of the Johnson & Johnson enterprise supply chain, he led the development of strategies to further establish and create new business services including safe and secure supply chain (i.e. anti-counterfeit, serialization, track and trace), enterprise-wide internal and external technology standards (enterprise master data, GS1, UDI, RFID), and new channel management strategies (ecommerce, demand sensing, distribution and transportation optimization).

Orlando holds a Bachelor of Science in Electrical Engineering from Rutgers University. He has been actively involved in several industry forums focused to the development and adoption of industry standards, including the development and adoption of the ISBT-128 transfusion medicine, including current membership in the US GS1 technical advisory group. He is a member of the program advisory board for the graduate supply chain program of Fairleigh Dickinson University, Silberman College of Business. He is an active speaker for the South Asian Professional Network Association (SAPNA) and Hispanic Organization for Leadership and Achievement (HOLA) enterprise groups, and a sponsor for the African American Leadership Council (AALC). He is active in his community, especially on activities focused on raising awareness of social and health issues.

 

Sarah Dye

Vice President
Optum

As Vice President of Oncology and Specialty Pharmaceuticals with Optum’s Medical Benefit Management division, Sarah has responsibility for a comprehensive solution set that includes the Cancer and Specialty Guidance Programs. Sarah is passionate about these complicated conditions and how Optum can help ensure consumers receive quality care and support services to help them navigate a complicated system.

Sarah Dye

Vice President
Optum

Sarah Dye

Vice President
Optum

As Vice President of Oncology and Specialty Pharmaceuticals with Optum’s Medical Benefit Management division, Sarah has responsibility for a comprehensive solution set that includes the Cancer and Specialty Guidance Programs. Sarah is passionate about these complicated conditions and how Optum can help ensure consumers receive quality care and support services to help them navigate a complicated system.

Sarah joined UnitedHealth Group in 2003 and held several other roles including leading Operations and Affordability with Optum International where she focused entirely on the Brazil health care market. Prior to Optum International, Sarah was Principal at UnitedHealth Group Ventures where she analyzed the market to identify new investment opportunities designed to create disruptive, positive change in the health care system.

Across her roles, Sarah uses her engineering training to perform root cause analysis to identify systemic issues in the health care and ultimately design new products to address these issues.  She successfully developed and launched new products in oncology, women’s health and orthopedics.

Sarah holds a bachelor’s degree in industrial engineering from Iowa State University.

 

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics
 

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology
 

Shirley O'Dea

CSO
Avectas

Shirley O'Dea

CSO
Avectas

Shirley O'Dea

CSO
Avectas
 

David C. Rhew, MD

Global Chief Medical Officer and VP of Healthcare
Microsoft

Dr. David C. Rhew is the Global Chief Medical Officer (CMO) and Vice-President (VP) of Healthcare for Microsoft. He is the Chairman of the Health and Fitness Technology Division for the Consumer Technology Association and serves on CTA’s Board of Industry Leaders. He co-holds six U.S. technology patents that enable authoring, mapping, and integration of clinical decision support into the electronic health record. David is currently an Adjunct Professor at the Stanford University School of Medicine.

David C. Rhew, MD

Global Chief Medical Officer and VP of Healthcare
Microsoft

David C. Rhew, MD

Global Chief Medical Officer and VP of Healthcare
Microsoft

Dr. David C. Rhew is the Global Chief Medical Officer (CMO) and Vice-President (VP) of Healthcare for Microsoft. He is the Chairman of the Health and Fitness Technology Division for the Consumer Technology Association and serves on CTA’s Board of Industry Leaders. He co-holds six U.S. technology patents that enable authoring, mapping, and integration of clinical decision support into the electronic health record. David is currently an Adjunct Professor at the Stanford University School of Medicine.

Dr. Rhew received his Bachelors of Science degrees in computer science and cellular molecular biology from the University of Michigan. He received his MD degree from Northwestern University and completed internal medicine residency at Cedars-Sinai Medical Center. He completed fellowships in health services research at Cedars-Sinai and infectious diseases at the University of California, Los Angeles.

He has served as CMO and VP for Samsung; Senior Vice-President and CMO at Zynx Health Incorporated; clinician/researcher in the Division of Infectious Diseases at the VA Greater Los Angeles Healthcare System; and Associate Clinical Professor of Medicine at UCLA. Dr. Rhew has served on the National Quality Forum’s (NQF) Executive Committee for Consensus Standards and Approval.

 

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr.

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking  of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.

 

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech
 

Christine E. Brown

Professor
City of Hope

Christine E. Brown

Professor
City of Hope

Christine E. Brown

Professor
City of Hope
 

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

 

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc
 

Seshu Tyagarajan

Global Program & Portfolio CMC Team Leader, CAR-T
Novartis

Seshu Tyagarajan

Global Program & Portfolio CMC Team Leader, CAR-T
Novartis

Seshu Tyagarajan

Global Program & Portfolio CMC Team Leader, CAR-T
Novartis
 

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies
 

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics
 

Steve Lynum

Executive Director
PHC Corporation (Japan)

Steve Lynum

Executive Director
PHC Corporation (Japan)

Steve Lynum

Executive Director
PHC Corporation (Japan)
 

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center
 

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society
 

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology
 

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association
 

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda
 

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics
 

Paul Rennert

Chief Scientific Officer
Aleta

Paul Rennert

Chief Scientific Officer
Aleta

Paul Rennert

Chief Scientific Officer
Aleta
 

Steve Shamah

Head of Research
Obsidian Therapeutics

Steve Shamah

Head of Research
Obsidian Therapeutics

Steve Shamah

Head of Research
Obsidian Therapeutics
 

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital
 

Ran Reshef

Associate Professor
Columbia University

Ran Reshef

Associate Professor
Columbia University

Ran Reshef

Associate Professor
Columbia University
 

Haro Hartounian

Senior Executive Director
BioPharma Innovation

Haro Hartounian

Senior Executive Director
BioPharma Innovation

Haro Hartounian

Senior Executive Director
BioPharma Innovation
 

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota
 

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta
 

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma
 

Roman Yelensky

CTO
Gritstone Oncology

Roman Yelensky

CTO
Gritstone Oncology

Roman Yelensky

CTO
Gritstone Oncology
 

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR
 

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals
 

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC
 

Friedrich Graf Finckenstein

Chief Medical Officer
Iovance Biosciences

Friedrich Graf Finckenstein

Chief Medical Officer
Iovance Biosciences

Friedrich Graf Finckenstein

Chief Medical Officer
Iovance Biosciences
 

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics
 

Zonghai Li

Founder, CEO and CSO
CARSgen

Zonghai Li

Founder, CEO and CSO
CARSgen

Zonghai Li

Founder, CEO and CSO
CARSgen
 

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda
 

Hans Klingemann

VP, Research and Development
NantKwest

Hans Klingemann

VP, Research and Development
NantKwest

Hans Klingemann

VP, Research and Development
NantKwest
 

Dr Robert Hariri

Founder and CEO
Cellularity

Dr Robert Hariri

Founder and CEO
Cellularity

Dr Robert Hariri

Founder and CEO
Cellularity
 

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics
 

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2
 

Prof. Alan Trounson

CEO
Cartherics

Prof. Alan Trounson

CEO
Cartherics

Prof. Alan Trounson

CEO
Cartherics
 

David Martin

CSO
Xyphos

David Martin

CSO
Xyphos

David Martin

CSO
Xyphos
 

Hans Brok

President
PHC Corporation of North America

Hans Brok

President
PHC Corporation of North America

Hans Brok

President
PHC Corporation of North America
 

Dr. Maria Fardis

President and Chief Executive Officer
Iovance Biotherapeutics

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr.

Dr. Maria Fardis

President and Chief Executive Officer
Iovance Biotherapeutics

Dr. Maria Fardis

President and Chief Executive Officer
Iovance Biotherapeutics

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

TESTIMONIALS

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

The Agenda

We are in the process of building the OCTS agenda for 2021 - formerly the CAR-T Congress. In the meantime, you can download the OCTS agenda from our virtual summit in July 2020 for a glimpse of what we were up to this year. Watch this space for the launch of the 2021 agenda, we look forward to having you back...

Download agenda

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Thursday, September 17, 2020 to Wednesday, June 30, 2021
Academics
$1499 + VAT
Standard pricing
Thursday, September 17, 2020 to Wednesday, June 30, 2021
Small Biotechs
$1599 + VAT
Standard pricing
Thursday, September 17, 2020 to Wednesday, June 30, 2021
Pharma
$2099 + VAT
Standard pricing
Thursday, September 17, 2020 to Wednesday, June 30, 2021
Service Providers
$2499
Standard pricing
Preparing registration...

Book a Team to Save More!

PLEASE NOTE: Team Discounts are only available for Industry Pricing

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Combined CAR-T Congress Europe:

  • Please note that a £49 processing fee will apply to any invoices requested.
  • All Prices are in GBP and are exclusive of VAT @ 20%
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined with any other offer.
  • Please view our Cancellation Policy.
  • QUESTIONS? Please email [email protected].

Pass Features:

  • 2 Day conference pass
  • Networking Sessions
  • Lunch and Refreshments
  • Complimentary Articles and Content

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.